405 related articles for article (PubMed ID: 15631542)
1. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis.
Bielory L; Lien KW; Bigelsen S
Drugs; 2005; 65(2):215-28. PubMed ID: 15631542
[TBL] [Abstract][Full Text] [Related]
2. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis.
Castillo M; Scott NW; Mustafa MZ; Mustafa MS; Azuara-Blanco A
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD009566. PubMed ID: 26028608
[TBL] [Abstract][Full Text] [Related]
3. Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy: current trends.
Ben-Eli H; Solomon A
Curr Opin Allergy Clin Immunol; 2018 Oct; 18(5):411-416. PubMed ID: 30020258
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulators for conjunctivitis.
Pacharn P; Vichyanond P
Curr Opin Allergy Clin Immunol; 2013 Oct; 13(5):550-7. PubMed ID: 23974685
[TBL] [Abstract][Full Text] [Related]
5. Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis.
Noble S; McTavish D
Drugs; 1995 Dec; 50(6):1032-49. PubMed ID: 8612470
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic options in ocular allergic disease.
Hingorani M; Lightman S
Drugs; 1995 Aug; 50(2):208-21. PubMed ID: 8521755
[TBL] [Abstract][Full Text] [Related]
7. Drugs for allergic rhinitis and allergic conjunctivitis.
Med Lett Drugs Ther; 2021 Apr; 63(1622):57-64. PubMed ID: 33848281
[No Abstract] [Full Text] [Related]
8. Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness.
Owen CG; Shah A; Henshaw K; Smeeth L; Sheikh A
Br J Gen Pract; 2004 Jun; 54(503):451-6. PubMed ID: 15186569
[TBL] [Abstract][Full Text] [Related]
9. Optimal use of topical agents for allergic conjunctivitis.
Mösges R; Hassan HA; Wenzel MR
BioDrugs; 1997 Oct; 8(4):250-64. PubMed ID: 18020517
[TBL] [Abstract][Full Text] [Related]
10. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model.
Abelson MB; Lanier RQ
Acta Ophthalmol Scand Suppl; 1999; (228):53-6. PubMed ID: 10337434
[TBL] [Abstract][Full Text] [Related]
11. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
Crampton HJ
Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
Spangler DL; Abelson MB; Ober A; Gotnes PJ
Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
[TBL] [Abstract][Full Text] [Related]
13. Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study.
Figus M; Fogagnolo P; Lazzeri S; Capizzi F; Romagnoli M; Canovetti A; Iester M; Ferreras A; Rossetti L; Nardi M
Eur J Ophthalmol; 2010; 20(5):811-8. PubMed ID: 20383847
[TBL] [Abstract][Full Text] [Related]
14. Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis.
Dechant KL; Goa KL
Drugs; 1991 Feb; 41(2):202-24. PubMed ID: 1709851
[TBL] [Abstract][Full Text] [Related]
15. Allergic conjunctivitis and H1 antihistamines.
del Cuvillo A; Sastre J; Montoro J; Jáuregui I; Dávila I; Ferrer M; Bartra J; Mullol J; Valero A
J Investig Allergol Clin Immunol; 2009; 19 Suppl 1():11-8. PubMed ID: 19476049
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
Avunduk AM; Tekelioglu Y; Turk A; Akyol N
Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
[TBL] [Abstract][Full Text] [Related]
17. [Seasonal and Perennial Allergic Rhinoconjunctivitis].
Schröder K; Finis D; Meller S; Buhren BA; Wagenmann M; Geerling G
Laryngorhinootologie; 2017 Feb; 96(2):89-97. PubMed ID: 28291999
[TBL] [Abstract][Full Text] [Related]
18. Interactions of olopatadine and selected antihistamines with model and natural membranes.
Brockman HL; Momsen MM; Knudtson JR; Miller ST; Graff G; Yanni JM
Ocul Immunol Inflamm; 2003 Dec; 11(4):247-68. PubMed ID: 14704897
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
[TBL] [Abstract][Full Text] [Related]
20. Antihistamines: topical vs oral administration.
Davies RJ; Bagnall AC; McCabe RN; Calderon MA; Wang JH
Clin Exp Allergy; 1996 May; 26 Suppl 3():11-7. PubMed ID: 8735853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
